GSGeoffrey Smelski

Geoffrey Smelski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Geoffrey Smelski has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ultrasound Detected Myokymia Is Associated with Increased Duration of Hospitalization and Healthcare Cost After Rattlesnake Bite in Arizona

    by Farshad Mazda Shirazi, Srikar R. Adhikari, Vance G. Nielsen, Geoffrey Thomas Smelski

    Neurotoxic envenomation by rattlesnakes has been of great concern throughout the Americas and in Arizona. In addition to clinical weakness, patients sometimes display myokymia, a disordered fasciculation of skeletal muscle, which is mediated by Mojave toxin. As neurotoxic venoms have been associated with increased release of creatine kinase (CK) activity and concordant increases in length of stay (LOS) in the hospital, it was retrospectively determined if point-of-care ultrasound detected myokymia at the bite site was associated with increased CK activity, LOS, and healthcare cost compared to rattlesnake envenomations not associated with myokymia. The Arizona Poison and Drug Information Center patient database was queried for patients with point-of-care ultrasound exam results at or near the bite site from 2017 to 2021. Using point-of-care ultrasound to detect subclinical myokymia, thirty-seven patients that met inclusion criteria were determined to have myokymia (n = 16) and/or not display it (n = 21). Patients with myokymia had twice the CK activities, double the LOS, and two-fold the healthcare costs of patients without myokymia detected. These findings serve as a rationale for future investigations to link ultrasound detected myokymia with patient outcomes.

  • Wilderness Medical Society Clinical Practice Guidelines for the Treatment of Pit Viper Envenomations in the United States and Canada: 2026 Update

    by Nicklaus Brandehoff, Spencer Greene, Jordan Benjamin, Sean P. Bush, Michael D. Cardwell, Alyrene Dorey, Jason Folt, Charles J. Gerardo, Geoffrey Smelski, Hank Song, et al.

    The Wilderness Medical Society convened an expert panel to develop a set of evidence-based guidelines for the prevention and treatment of North American pit viper envenomations, and this serves as an update to the initial guidelines. We present a review of pertinent pathophysiology and discuss prevention measures and therapeutic management. Graded recommendations are made regarding each treatment and its role in management. This significant update to the prior guidelines includes a discussion of F ( ab ′) 2 antivenom treatment, which was not previously approved by the Food and Drug Administration. These guidelines should assist in clinical decision making, but a cookbook approach is often insufficient, because each patient is unique and may respond differently to therapeutics. Physicians must use their experience and frequent clinical assessments to apply these recommendations to their individual patients. Consultation with a local toxicologist familiar with envenomations or a poison control center is recommended to assist in patient management. These guidelines are for crotaline snakes native to the United States and Canada and should not be applied to other snake species or geographic regions. Coral snake envenomations result in fewer serious side effects (<3% of victims) and account for only 1 to 3% of all snakebites reported in the United States and Canada. Due to the differences in management, coral snakes are not covered in these guidelines. This is an updated version of the guidelines published in 2015.


  • Open Access

    Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain

    by Vance G. Nielsen, Darien L. Stratton, Tyler M. Hoelscher, Hannah L. Nakamura, Matthew M. Cornelison, William F. Rushton, Geoffrey T. Smelski

    The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied. We reviewed poison center charts of rattlesnake envenomations between 1 January 2018, and 31 December 2022. Demographic data as well as details of antivenom usage and pain severity were collected. Patients were coded in one of three categories: without pain (Pain 0), well controlled pain (Pain 1), and opioid refractory pain (Pain 2). A total of 289 patients met the inclusion criteria, with 140 receiving Anavip antivenom and 149 receiving Crofab. Patient characteristics were different between both cohorts. There were no significant differences in the number of Anavip vials used between the Pain 1 and Pain 2 groups. However, patients in the Crofab Pain 2 group received more antivenom compared to Pain 1. Importantly, Pain 3 patients were treated with the highest amount of antivenom in both the Crofab and Anavip cohorts. Despite the higher doses of antivenom used, these patients also experienced the greatest pain. These data suggest that antivenom alone may have minimal analgesic benefits.


  • Evaluation of the International Society on Thrombosis and Haemostasis definition of major bleeding in Arizona rattlesnake bites

    by Geoffrey Smelski, Sarah A. Watkins, Bryan Wilson, Jennifer Ramirez, Farshad Mazda Shirazi, Frank G. Walter

    IntroductionIn 2023, a group of experts proposed that a definition of major bleeding in pharmaceutically anticoagulated patients be used in all snakebite trials. This includes bleeding that results in death, is life-threatening, causes chronic sequelae, or consumes major healthcare resources, including bleeding into a major area or hemoglobin concentration decrease >= 20 g/L. We hypothesized that a decline in hemoglobin concentration >= 20 g/L is common but rarely clinically significant in our population of Arizona rattlesnake bite patients.MethodsPoison center records of rattlesnake bites in humans from 2018 through 2022 were retrospectively reviewed and assessed for major bleeding by the above criteria.ResultsFour hundred and eighty-one patients met the inclusion criteria, of whom 265 (55.1%) had a hemoglobin concentration decrease >= 20 g/L. No patients died, and there was no evidence of bleeding into a critical organ. Three patients (1.1%) received blood transfusions. A decrease in hemoglobin concentration >= 20 g/L was 100% sensitive for identifying the major bleeding-associated outcomes; however, specificity was only 45.2%. Measures of healthcare utilization and chronic sequelae were somewhat higher in patients with a decrease in hemoglobin concentration >= 20 g/L.DiscussionLaboratory manifestations of hemotoxicity were common in this population, but hemorrhage was rare. While over half of patients met the major bleeding criterion of a decline in hemoglobin concentration >= 20 g/L, only 1.1% had bleeding that was potentially life-threatening as measured by receipt of a red blood cell transfusion. None died or had bleeding into a critical area. While nonspecific for major bleeding, a drop in hemoglobin concentration correlated with worse envenomation severity: these patients received more vials of antivenom, had a higher medical bill, a longer hospital stay, and were less likely to report full recovery at 90 days.ConclusionsA decrease in hemoglobin concentration >= 20 g/L should not be used as evidence of major bleeding for Arizona rattlesnake envenomation studies, but it may have a role as an indirect marker of envenomation severity.


  • Twenty-five years of suspected rattlesnake encounters in Arizona

    by Hannah Nakamura, Thomas Maciulewicz, Jennifer Ramirez, Bryan Hughes, David R. Axon, Farshad Shirazi, Geoffrey Smelski

    Introduction: Rattlesnake (Crotalus spp., Sistrurus spp.) bites in the southwestern United States are associated with significant morbidity. This study aims to describe 25 years of rattlesnake encounters reported to the Arizona Poison and Drug Information Center to identify vulnerable populations and circumstances where encounters occur to create public education to reduce future bites. Methods: Cases of suspected rattlesnake encounters in Arizona reported to the Arizona Poison and Drug Information Center between 1999 and 2023 were analyzed to identify populations and circumstances associated with encounters. Results: A total of 3,808 cases were analyzed overall and by age subgroups. Most encounters occurred in men (69.9%), during the evening (16:00-21:59; 49.2%), in summer (41.9%), and close to home (38.2%). Most bites occurred to the lower extremity (51%). Children 0 to 12-years-old have more encounters than those 13-years-old and older in rural zip codes (27.7% versus 14.8%; P = 0.005), during spring (31.8% versus 22.3%; P = 0.0005), and during the evening (64.4% versus 48.1%; P < 0.001). Discussion: Rattlesnakes are encountered when rattlesnake and human behavior patterns overlap. Many people spend time outside during evening hours in the summer, and valuable resources like food, water, and shelter can be found near houses where humans spend much of their time. Most age groups have similar encounter circumstances but encounters among children 0 to 12-years-old differ in time of day, season, and urbanization level than encounters of those 13-years-old and older. Limitations of this study include underreporting of encounters, incomplete case details, potential reporting bias, potential snake misidentification, and geographic coverage of the poison center. Conclusion: Prevention of rattlesnake bites by reducing encounters is the most effective way to reduce suffering and healthcare costs. Future steps include creating and disseminating targeted public health education using the data collected.


  • Open Access

    Neurotoxic respiratory failure absent following Arizona rattlesnake bites

    by Geoffrey Smelski, Michael Cardwell, Jaiva Larsen